SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
- 1 October 2018
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 18 (10), 629-635
- https://doi.org/10.1016/j.clml.2018.07.293
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysisLeukemia, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndromeNature Medicine, 2009
- Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotypeNature Medicine, 2009
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideProceedings of the National Academy of Sciences of the United States of America, 2009
- Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancerLeukemia, 2009
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disordersBlood, 2007
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences of the United States of America, 2007
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood, 2004